Start-up biotech Accuri Cytometers’ launch this week of a $25,000 flow cytometer may be occurring at the cusp of what is widely believed to be a re-emergence for the technology in non-traditional application areas.
 
And, as companies such as Accuri, Guava, and Becton Dickinson, as well as individual researchers, continue to explore ways to exploit flow cytometry’s throughput potential, many believe that drug-discovery applications are right around the corner.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.